Trevi Therapeutics Inc. (TRVI)
TRVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TRVI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001563880 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $27.8M cash; operating cash flow -$15.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 142,559,400 (2026-10-31); 128,230,134 a year earlier; 63,857,622 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-04-17 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, New York, New York, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $594K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$21.5M | -$19.7M | $27.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$17.8M | -$17.4M | $54.3M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$13.2M | -$16.7M | $19.4M | No debt tags | Needs four quarters | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | Not filed | -$8.3M | -$7.6M | $18.9M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | Not filed | -$11.8M | -$10.9M | $56.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$12.3M | -$10.1M | $117.1M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$10.3M | -$13.5M | $19.4M | No debt tags | Needs four quarters | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | Not filed | -$11.4M | -$9.6M | $34.1M | No debt tags | Needs four quarters | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-17 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 540 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.7% |
| 1 month | +11.1% |
| 3 months | -24.8% |
| Year to date | +9.0% |
| 1 year | +19.1% |
| From 52-week high | -30.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
| MRVI | Maravai LifeSciences Holdings Inc. | $7.40 | -1.86% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier